Randomized comparison of ticagrelor versus prasugrel in ST elevation myocardial infarction

Описание к видео Randomized comparison of ticagrelor versus prasugrel in ST elevation myocardial infarction

Additional effective antiplatelet agents in your armamentarium for treating patients with STEMI are always welcome. Before the Prague 18 trial, two of these – prasugrel and ticagrelor – had each been compared separately to clopidogrel, but had never been compared directly to each other. Join Dejan Milasinovic (Serbia) as he reports from ESC Congress 2016 the details of this illuminating trial: What were the primary and secondary endpoints? How did each of these agents perform? What is the importance of the so-called “neutral” results? Learn why the results of Prague 18 offer additional choices for DAPT today…

For more on this subject, please visit https://www.pcronline.com/

Комментарии

Информация по комментариям в разработке

Похожие видео